Thursday, November 28, 2013

Videorecording of consent for clinical trials mandatory

 The Union Health Ministry has made audio-visual recording of the informed consent of each subject mandatory in a clinical trial. This is in addition to obtaining his/her written consent.

This decision comes in the wake of the Supreme Court pulling up the Ministry for lack of transparency in clinical trials.In its October 21, 2013, order on a writ petition filed by an NGO, the Swasthya Adhikar Manch, Indore, the court said with respect to five global clinical trials, which was approved by the Drugs Controller-General of India (DCGI) office from January 1, 2013, to August 31, 2013, an appropriate provision should be made or administrative direction issued, ensuring that audio-visual recording of the informed consent process was done and the documentation preserved, adhering to confidentiality principles.
In his order, DCGI G.N. Singh said all sponsors/investigators/institutes/organisations and other stakeholders involved in clinical trials should adhere to this requirement with immediate effect.

Reacting to this, the Indian Society for Clinical Research — an association of professionals involved in clinical trials — said lack of guidance and direction on operational and logistical issues of managing the audio-visual recording process like the kind of equipment to be used, and where and how information should be stored could leave room for ambiguity and inconsistencies in execution.

More clarity was required on how confidentiality of patients should be protected and maintained in an ‘audio-visual’ context and what processes needed to be followed in instances where, for religious and socio-cultural reasons, patients might not want to be videographed, the association said. 

Source: The Hindu

Tuesday, November 26, 2013

5th Annual Biosimilars Evolution Congress

Day 1 – 10th April, 2014
Meet : Key note on Future of biosimilar industry

Sessions :
  • Master class: Indian regulatory landscape
  • Comparative study of regulatory guidelines between Developed and Emerging markets
  • White Paper Submission: Examining the benefits of Product specific guidelines to have a single regulatory guideline across the globe
  • Understanding Regulations and challenges in developing countries to device a proper entrance strategy

R&D Sessions:
  • Face Off: R&D in India is not as per international levels, what is required to bring it to that level
  • Understanding the future of QbD in biologics to make sure your companies processes and technologies are refined for Qbd implementation
  • Case study: Approach of big companies in terms of R&D
  • Understanding the aspects of tech transfer to develop a proper process for the same in your organisation.

Day 2 – 11th April, 2014
Meet: Opening remarks from the Chair

Sessions:
  • Panel Discussion: Ensuring the use of non infringing formulations to ease out the process of regulatory approval
  • Studying the patent landscape carefully to get a better understanding of its effect on your organisation
  • Panel Discussion: Changes required for a creating talent pool with university tie-ups for biosimilar R&D in India

Manufacturing Sessions:
  • Understanding how to create a quality biosimilar at par with innovator molecules to build a strong product portfolio for your company.
  • Learning about the outsourcing options available for manufacturing to choose the best fit for your organisation
  • Panel discussion: Why is the manufacturing of biosimilars slow in India, Evaluating how to implement best practices to fast track drug production in India
  • Building ways of tackling multiple product manufacturing to make sure your organisation has the right environment for each product
  • Outsource it to us: 4 vendor presentation of 15 mins each from manufacturing facilities that do outsourced work
Who Should Attend!
R&D heads, Manufacturing Heads, Regulatory Heads, Biosimilar heads, VPs and General managers Chief Scientific officers